Top Markets
#1 SSV Network SSV Network +22.92%
#2 EXOD EXOD +22.08%
#3 Derive Derive +21.36%
#4 Velvet Velvet +21.35%
#5 The Black Bull The Black Bull +21.24%
#6 XPIN Network XPIN Network +18.75%
#7 Binance-Peg Bitcoin Cash Binance-Peg Bitcoin Cash +18.45%
#8 wojak wojak +18.32%
#9 Bitcoin Cash Bitcoin Cash +18.11%
#10 Arowana Arowana +17.65%
Coin of the day
SSV Network SSV Network
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Apollomics, Inc. Apollomics, Inc.

Apollomics, Inc.

APLM
Rang in aandelen #25256
Apollomics, Inc., a biotechnology enterprise established in 2015 and... Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Aandeelprijs
$23.57
Laatst gesynchroniseerd: 2026-08-20
Marktkapitalisatie
$51.76M
Verandering (1 dag)
-0.08%
Verandering (1 jaar)
289.59%
Land
US
Handel Apollomics, Inc. (APLM)

Categorie

Healthcare
Winst voor Apollomics, Inc. (APLM)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Apollomics, Inc. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Apollomics, Inc. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US